116 years of building, sharing and reinvesting in knowledge
A rich
legacy
Founded in 1908 and headquartered in Denmark, we are majority owned by the LEO Foundation
Medical dermatology
Dedicating decades of research and development to advance the science of dermatology
Our
purpose
Advancing the standard of care for the benefit of people with skin conditions, their families and society
NEWS ARTICLE
LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%
In Q1, LEO Pharma continued its robust growth, driven by dermatology, and made significant strategic progress. This included expanding the launch of Anzupgo® to five markets...
Ballerup, Denmark, May 15, 2025
2025 Q1 Results- 09/07/25 LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy
- 03/06/25 LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)
- 02/06/25 LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs
Our performance and results
LEO Pharma's Annual Report covers our financial and sustainability reporting for the financial year from January 1 to December 31.
Read our 2024 Annual Report
CAREER
Discover how we innovate collectively.
For us, collaborating innovatively means continuously enhancing and expanding what's achievable for one another, our company, and our patients.
Learn more
